Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
SALMETEROL XINAFOATE FLUTICASONE PROPIONATE
PCO Manufacturing
SALMETEROL XINAFOATE FLUTICASONE PROPIONATE
25/125 Microgram
Pressurised Inhalation Suspension
Product subject to prescription which may be renewed (B)
Authorised
0000-00-00
_ _ _ _ _ _ PACKAGE LEAFLET: INFORMATION FOR THE USER SERETIDE 50 EVOHALER ® 25 MICROGRAM/50 MICROGRAM/DOSE, PRESSURISED INHALATION, SUSPENSION. SERETIDE 125 EVOHALER ® 25 MICROGRAM/125 MICROGRAM/DOSE, PRESSURISED INHALATION, SUSPENSION. SERETIDE 250 EVOHALER ® 25 MICROGRAM/250 MICROGRAM/DOSE, PRESSURISED INHALATION, SUSPENSION. Salmeterol & Fluticasone Propionate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist, This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET: 1. What Seretide is and what it is used for 2. Before you use Seretide 3. How to use Seretide 4. Possible side effects 5. How to store Seretide 6. Further Information 1. WHAT SERETIDE IS AND WHAT IT IS USED FOR Seretide contains two medicines, salmeterol and fluticasone propionate: Salmeterol is a long-acting bronchodilator. Bronchodilators help the airways in the lung to stay open. This makes it easier for air to get in and out. The effects last for at least 12 hours. Fluticasone propionate is a corticosteroid which reduces swelling and irritation in the lungs. The doctor has prescribed this medicine to help prevent breathing problems such as asthma. You Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Seretide 125 Evohaler 25 microgram/125 microgram/dose pressurised inhalation suspension 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each single actuation of Seretide provides 25 micrograms of salmeterol (as salmeterol xinafoate) and 125 micrograms of fluticasone propionate (delivered from the valve). This is equivalent to 21 micrograms of salmeterol and 110 micrograms of fluticasone propionate delivered from the actuator (delivered dose). For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Pressurised inhalation, suspension _Product imported from Belgium, Greece, Hungary and the UK:_ The canister contains a white to off white suspension. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Seretide is indicated in the regular treatment of asthma where use of a combination product (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate: - patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta-2-agonist or - patients already adequately controlled on both inhaled corticosteroid and long-acting beta-2-agonist. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Seretide Evohaler is for inhalation use only. Patients should be made aware that Seretide Evohaler must be used daily for optimum benefit, even when asymptomatic. Patients should be regularly reassessed by a doctor, so that the strength of Seretide they are receiving remains optimal and is only changed on medical advice. THE DOSE SHOULD BE TITRATED TO THE LOWEST DOSE AT WHICH EFFECTIVE CONTROL OF SYMPTOMS IS MAINTAINED. WHERE THE CONTROL OF SYMPTOMS IS MAINTAINED WITH THE LOWEST STRENGTH OF THE COMBINATION GIVEN TWICE DAILY THEN THE NEXT STEP COULD INCLUDE A TEST OF INHALED CORTICOSTEROID ALONE. Read the complete document